JonesResearch adjusted the firm’s price target on Monopar Therapeutics to $9 from $2 and keeps a Buy rating on the shares following the 1:5 reverse stock split. The company’s Phase I trial of imaging agent MNPR-101-Zr is active and enrolling participants, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics Begins Phase 1 Trial of MNPR-101-Zr
- Monopar announces initial data for first patient dosed in trial of MNPR-101-Zr
- Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
- Monopar Therapeutics Inc trading halted, news pending
- Upcoming Stock Splits This Week (August 12 to August 16) – Stay Invested